CELGENE CORPORATION

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Safety Study of CC-292 and Rituximab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Phase 1

Completed

Conditions: Leukemia Lymphocytic Chronic B-Cell

Interventions: Drug: CC-292
Drug: Rituximab

First Posted Date: 2012-12-07

Last Posted Date: 2016-04-19

Lead Sponsor: Celgene Corporation

Target Recruit Count: 40

Registration Number: NCT01744626

Locations: 🇺🇸
Hackensack UMC, Hackensack, New Jersey, United States
🇺🇸
The West Clinic, Memphis, Tennessee, United States
🇩🇪
Universitätsklinik Ulm, Ulm, Bayern, Germany

and more 5 locations

Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Phase 3

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Pomalidomide
Drug: Bortezomib
Drug: Dexamethasone

First Posted Date: 2012-11-28

Last Posted Date: 2023-06-06

Lead Sponsor: Celgene

Target Recruit Count: 559

Registration Number: NCT01734928

Locations: 🇺🇸
Western Kentucky Hematology and Oncology Group, PSC, Paducah, Kentucky, United States
🇺🇸
Local Institution - 132, Bangor, Maine, United States
🇺🇸
St. Agnes - Medical Center, Baltimore, Maryland, United States

and more 318 locations

2-part Study to Assess Safety, Pharmacokinetics & Pharmacodynamics of CC-220 & Effect of Food on CC-220 in Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: CC-220 2 mg
Drug: CC-220 0.03 mg
Drug: CC-220 0.1 mg
Drug: CC-220 0.3 mg
Drug: CC-220 1 mg
Drug: Placebo
Drug: CC-220

First Posted Date: 2012-11-27

Last Posted Date: 2019-11-12

Lead Sponsor: Celgene

Target Recruit Count: 65

Registration Number: NCT01733875

Locations: 🇺🇸
Covance Clinical Research Unit, Madison, Wisconsin, United States

Safety Study of CC-292 and Lenalidomide in Subjects With Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma

Phase 1

Completed

Conditions: Leukemia Lymphocytic Chronic B-Cell

Interventions: Drug: CC-292
Drug: Lenalidomide

First Posted Date: 2012-11-26

Last Posted Date: 2019-12-20

Lead Sponsor: Celgene

Target Recruit Count: 20

Registration Number: NCT01732861

Locations: 🇦🇹
Universitatsklinik der PMU, Salzburg, Austria
🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇦🇹
Medizinische Abteilung-Zentrum fur Onkologie und Hamatologie, Wien, Austria

and more 8 locations

A Phase 2 Study of Lenalidomide in Patients With Relapsed or Recurrent Adult T-cell Leukemia-lymphoma

Phase 2

Completed

Conditions: Adult T-Cell Leukemia-Lymphoma

Interventions: Drug: Lenalidomide

First Posted Date: 2012-11-09

Last Posted Date: 2018-05-29

Lead Sponsor: Celgene

Target Recruit Count: 26

Registration Number: NCT01724177

Locations: 🇯🇵
National Cancer Center Hospital East, Kashiwa, Chiba, Japan
🇯🇵
Kumamoto University Hospital, Kumamoto, Japan
🇯🇵
Kagoshima University Medical and Dental Hospital, Kagoshima, Japan

and more 15 locations

Evaluation of Safety of Pomalidomide in Combination With Dexamethasone (Low Dose) in Patients With Refractory or Relapsed and Refractory Multiple Myeloma

Phase 3

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Pomalidomide
Drug: Dexamethasone

First Posted Date: 2012-10-24

Last Posted Date: 2022-01-10

Lead Sponsor: Celgene

Target Recruit Count: 682

Registration Number: NCT01712789

Locations: 🇦🇹
Medical University of Graz, Graz, Austria
🇦🇹
Medizinische Universitat Innsbruck, Innsbruck, Austria
🇦🇹
Wilhelminenspital Vienna, Vienna, Austria

and more 109 locations

Effect of P-glycoprotein Inhibition on Lenalidomide Pharmacokinetics in Healthy Males

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Lenalidomide
Drug: Temsirolimus
Drug: Quinidine
Drug: Diphenhydramine

First Posted Date: 2012-10-24

Last Posted Date: 2019-11-08

Lead Sponsor: Celgene

Target Recruit Count: 31

Registration Number: NCT01712828

Locations: 🇺🇸
Covance Clinical Research Unit Dallas, Dallas, Texas, United States

A Phase 1 Open-Label Study to Evaluate the Effect of CYP450 and P-gp Inhibition and Induction on the Pharmacokinetics of Pomalidomide (CC-4047) in Healthy Male Subjects

Phase 1

Completed

Conditions: Healthy
Pharmacology, Clinical

Interventions: Drug: Pomalidomide
Drug: Ketoconazole
Drug: Carbamazepine
Drug: Fluvoxamine

First Posted Date: 2012-10-16

Last Posted Date: 2019-11-12

Lead Sponsor: Celgene

Target Recruit Count: 32

Registration Number: NCT01707407

Locations: 🇺🇸
Covance Research Unit, Inc, Madison, Wisconsin, United States

A Phase 2 Study of Lenalidomide to Evaluate the Efficacy in Japanese Patients With Newly Diagnosed Multiple Myeloma

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Lenalidomide
Drug: dexamethasone

First Posted Date: 2012-10-03

Last Posted Date: 2018-11-08

Lead Sponsor: Celgene

Target Recruit Count: 26

Registration Number: NCT01698801

Locations: 🇯🇵
Iwate Medical University, Morioka, Iwate, Japan
🇯🇵
Tokai University Hospital, Isehara, Kanagawa, Japan
🇯🇵
National Disaster Medical Center, Tachikawa, Tokyo, Japan

and more 21 locations

Safety and Pharmacokinetics of AVL-292 Following Multiple Doses and the Effect of Food on the Single-dose Pharmacokinetics of AVL-292

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: 50 mg AVL-292
Drug: 100 mg AVL-292
Drug: 200 mg AVL-292
Drug: 350 mg AVL-292
Drug: Placebo capsules

First Posted Date: 2012-09-25

Last Posted Date: 2019-11-04

Lead Sponsor: Celgene

Target Recruit Count: 54

Registration Number: NCT01692184

Locations: 🇺🇸
Covance Clinical Research Unit, Dallas, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy